Hendrickson Carolyn M, Abbott Jason, Zhuo Hanjing, Liu Kathleen D, Calfee Carolyn S, Matthay Michael A
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California;
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L579-L585. doi: 10.1152/ajplung.00381.2016. Epub 2017 Feb 17.
The protein concentration of alveolar edema fluid in acute respiratory distress syndrome (ARDS) is dynamic. It reflects alveolar flooding during acute injury, as well as fluid and protein clearance over time. We hypothesized that among ARDS patients treated with low tidal volume ventilation, higher concentrations of protein in mini-bronchoalveolar lavage (mBAL) samples would predict slower resolution of lung injury and worse clinical outcomes. Total protein and IgM concentrations in mBAL samples from 79 subjects enrolled in the aerosolized albuterol (ALTA) ARDS Network Albuterol Trial were measured by colorimetric assay and ELISA, respectively. Linear regression models were used to test the association of mBAL proteins with clinical outcomes and measures of length of illness, including ventilator-free days (VFDs). Median mBAL total protein concentration was 1,740 μg/ml [interquartile range (IQR): 890-3,170]. Each 500 μg/ml increase in mBAL total protein was associated with an additional 0.8 VFDs [95% confidence interval (CI): 0.05-1.6, value = 0.038]. Median mBAL IgM concentration was 410 ng/ml (IQR: 340-500). Each 50 ng/ml increase in mBAL IgM was associated with an additional 1.1 VFDs (95% CI 0.2-2.1, value = 0.022). These associations remained significant and were not attenuated in multivariate models adjusted for age, serum protein concentration, and vasopressor use in the 24 h before enrollment. Thus, higher mBAL total protein and IgM concentrations at are associated with more VFDs in patients with ARDS and may identify patients with preserved alveolar epithelial mechanisms for net alveolar fluid clearance.
急性呼吸窘迫综合征(ARDS)患者肺泡水肿液中的蛋白质浓度是动态变化的。它反映了急性损伤期间的肺泡灌洗情况,以及随着时间推移的液体和蛋白质清除情况。我们推测,在接受低潮气量通气治疗的ARDS患者中,小支气管肺泡灌洗(mBAL)样本中较高的蛋白质浓度预示着肺损伤的缓解较慢且临床结局较差。通过比色法和酶联免疫吸附测定(ELISA)分别测量了参与雾化沙丁胺醇(ALTA)ARDS网络沙丁胺醇试验的79名受试者mBAL样本中的总蛋白和IgM浓度。采用线性回归模型来检验mBAL蛋白与临床结局以及疾病持续时间指标(包括无呼吸机天数,VFDs)之间的关联。mBAL总蛋白浓度中位数为1740μg/ml [四分位数间距(IQR):890 - 3170]。mBAL总蛋白每增加500μg/ml,与额外增加0.8个VFDs相关 [95%置信区间(CI):0.05 - 1.6,P值 = 0.038]。mBAL IgM浓度中位数为410ng/ml(IQR:340 - 500)。mBAL IgM每增加50ng/ml,与额外增加1.1个VFDs相关(95%CI 0.2 - 2.1,P值 = 0.022)。在针对年龄、血清蛋白浓度和入组前24小时血管升压药使用情况进行调整的多变量模型中,这些关联仍然显著且未减弱。因此,ARDS患者中较高的mBAL总蛋白和IgM浓度与更多的VFDs相关,并且可能识别出具有保留的肺泡上皮净肺泡液体清除机制的患者。